| Total n . | PDAC . | GEA . | CCA . | HCC . | |
|---|---|---|---|---|---|
| Cohorts (n, %) | 32 480 | 15 578 (48.0) | 8435 (26.0) | 6189 (19.1) | 2278 (7.0) |
| Male sex (n, %) | 19 084 (58.7) | 8251 (53.0) | 6080 (72.1) | 3055 (49.4) | 1697 (74.5) |
| Median age, years | 68 (18-102) | 69 (20-102) | 66 (18-100) | 68 (18-98) | 67 (16-97) |
| Percent newly diagnosed | 64.93 | 64.18 | 63.86 | 66.52 | 69.54 |
| BRAF alterations (n,%) | 969 (2.98) | 361 (2.3) | 219 (2.6) | 328 (5.3) | 61 (2.7) |
| BRAF V600E (class I) | 264 (0.81) | 79 (0.51) | 53 (0.63) | 114 (1.8) | 18 (0.79) |
| BRAF class II | 256 (0.79) | 117 (0.75) | 57 (0.68) | 69 (1.1) | 13 (0.57) |
| BRAF class III | 329 (1.01) | 103 (0.66) | 87 (1.03) | 119 (1.9) | 20 (0.88) |
| Other predicted driver | 120 (0.37) | 62 (0.40) | 22 (0.26) | 26 (0.40) | 10 (0.44) |
| Total n . | PDAC . | GEA . | CCA . | HCC . | |
|---|---|---|---|---|---|
| Cohorts (n, %) | 32 480 | 15 578 (48.0) | 8435 (26.0) | 6189 (19.1) | 2278 (7.0) |
| Male sex (n, %) | 19 084 (58.7) | 8251 (53.0) | 6080 (72.1) | 3055 (49.4) | 1697 (74.5) |
| Median age, years | 68 (18-102) | 69 (20-102) | 66 (18-100) | 68 (18-98) | 67 (16-97) |
| Percent newly diagnosed | 64.93 | 64.18 | 63.86 | 66.52 | 69.54 |
| BRAF alterations (n,%) | 969 (2.98) | 361 (2.3) | 219 (2.6) | 328 (5.3) | 61 (2.7) |
| BRAF V600E (class I) | 264 (0.81) | 79 (0.51) | 53 (0.63) | 114 (1.8) | 18 (0.79) |
| BRAF class II | 256 (0.79) | 117 (0.75) | 57 (0.68) | 69 (1.1) | 13 (0.57) |
| BRAF class III | 329 (1.01) | 103 (0.66) | 87 (1.03) | 119 (1.9) | 20 (0.88) |
| Other predicted driver | 120 (0.37) | 62 (0.40) | 22 (0.26) | 26 (0.40) | 10 (0.44) |
| Total n . | PDAC . | GEA . | CCA . | HCC . | |
|---|---|---|---|---|---|
| Cohorts (n, %) | 32 480 | 15 578 (48.0) | 8435 (26.0) | 6189 (19.1) | 2278 (7.0) |
| Male sex (n, %) | 19 084 (58.7) | 8251 (53.0) | 6080 (72.1) | 3055 (49.4) | 1697 (74.5) |
| Median age, years | 68 (18-102) | 69 (20-102) | 66 (18-100) | 68 (18-98) | 67 (16-97) |
| Percent newly diagnosed | 64.93 | 64.18 | 63.86 | 66.52 | 69.54 |
| BRAF alterations (n,%) | 969 (2.98) | 361 (2.3) | 219 (2.6) | 328 (5.3) | 61 (2.7) |
| BRAF V600E (class I) | 264 (0.81) | 79 (0.51) | 53 (0.63) | 114 (1.8) | 18 (0.79) |
| BRAF class II | 256 (0.79) | 117 (0.75) | 57 (0.68) | 69 (1.1) | 13 (0.57) |
| BRAF class III | 329 (1.01) | 103 (0.66) | 87 (1.03) | 119 (1.9) | 20 (0.88) |
| Other predicted driver | 120 (0.37) | 62 (0.40) | 22 (0.26) | 26 (0.40) | 10 (0.44) |
| Total n . | PDAC . | GEA . | CCA . | HCC . | |
|---|---|---|---|---|---|
| Cohorts (n, %) | 32 480 | 15 578 (48.0) | 8435 (26.0) | 6189 (19.1) | 2278 (7.0) |
| Male sex (n, %) | 19 084 (58.7) | 8251 (53.0) | 6080 (72.1) | 3055 (49.4) | 1697 (74.5) |
| Median age, years | 68 (18-102) | 69 (20-102) | 66 (18-100) | 68 (18-98) | 67 (16-97) |
| Percent newly diagnosed | 64.93 | 64.18 | 63.86 | 66.52 | 69.54 |
| BRAF alterations (n,%) | 969 (2.98) | 361 (2.3) | 219 (2.6) | 328 (5.3) | 61 (2.7) |
| BRAF V600E (class I) | 264 (0.81) | 79 (0.51) | 53 (0.63) | 114 (1.8) | 18 (0.79) |
| BRAF class II | 256 (0.79) | 117 (0.75) | 57 (0.68) | 69 (1.1) | 13 (0.57) |
| BRAF class III | 329 (1.01) | 103 (0.66) | 87 (1.03) | 119 (1.9) | 20 (0.88) |
| Other predicted driver | 120 (0.37) | 62 (0.40) | 22 (0.26) | 26 (0.40) | 10 (0.44) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
